Cargando…

Subcutaneous interleukin-2, interferon alpha-2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: a phase II trial

The association of interleukin-2 (IL-2), interferon alpha-2a (IFNα), 5-fluorouracil (5-FU) has been reported to induce response in metastatic renal cell carcinoma (MRCC). This study evaluated IL-2, IFNα and 5FU as second-line treatment after failure under immunotherapy. A total of 35 patients receiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ravaud, A, Trufflandier, N, Ferrière, J M, Debled, M, Palussière, J, Cany, L, Gaston, R, Mathoulin-Pélissier, S, Bui, B N
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2003
Materias:	Clinical
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395282/ https://www.ncbi.nlm.nih.gov/pubmed/14676797 http://dx.doi.org/10.1038/sj.bjc.6601419

Ejemplares similares

Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma.
por: Ravaud, A., et al.
Publicado: (1994)

Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study
por: Allen, M J, et al.
Publicado: (2000)

Interleukin 2 and interferon alpha-2a do not improve anti-tumour activity of 5-fluorouracil in advanced colorectal cancer.
por: Goey, S. H., et al.
Publicado: (1996)

Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics.
por: Seymour, M. T., et al.
Publicado: (1994)

Subcutaneous administration of interleukin 2 and interferon-alpha-2b in advanced renal cell carcinoma: a confirmatory study.
por: Facendola, G., et al.
Publicado: (1995)

Continuous infusion of 5-fluorouracil with alpha 2b interferon for advanced colorectal carcinoma.
por: Ferguson, J. E., et al.
Publicado: (1995)

A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer.
por: Jayson, G. C., et al.
Publicado: (1998)

Separate and combined analysis of successive dependent outcomes after breast-conservation surgery: recurrence, metastases, second cancer and death
por: Rondeau, Virginie, et al.
Publicado: (2010)

Thyroiditis after treatment with interleukin-2 and interferon alpha-2a.
por: Pichert, G., et al.
Publicado: (1990)

Dacarbazine (DTIC), human recombinant interferon alpha 2a (Roferon) and 5-fluorouracil for disseminated malignant melanoma.
por: Mulder, N. H., et al.
Publicado: (1992)

Cisplatin, 5-fluorouracil and interferon alpha 2b for recurrent or metastatic head and neck cancer.
por: Cascinu, S., et al.
Publicado: (1994)

Combination chemoimmunotherapy with monthly cycles of 5-fluorouracil + interferon-alfa-2b in previously-treated advanced cancer
por: Quan, Walter, et al.
Publicado: (2013)

The effect of 5-fluorouracil and alpha interferon and 5-fluorouracil and leucovorin on cellular anti-tumour immune responses in patients with advanced colorectal cancer.
por: Nichols, P. H., et al.
Publicado: (1994)

Variables with time-varying effects and the Cox model: Some statistical concepts illustrated with a prognostic factor study in breast cancer
por: Bellera, Carine A, et al.
Publicado: (2010)

Alpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer
Publicado: (2001)

The effects of 5-fluorouracil and interferon-alpha on early healing of experimental intestinal anastomoses.
por: de Waard, J. W., et al.
Publicado: (1996)

Immunomodulation during prolonged treatment with combined interleukin-2 and interferon-alpha in patients with advanced malignancy.
por: von Rohr, A., et al.
Publicado: (1993)

Thyroid dysfunction can predict response to immunotherapy with interleukin-2 and interferon-2 alpha.
por: Reid, I., et al.
Publicado: (1991)

Immunological effects of alternative weekly interferon-alpha-2b and low dose interleukin-2 in patients with cancer.
por: Fiorentino, B., et al.
Publicado: (1992)

Clinical Utility of Serum Interleukin-8 and Interferon-Alpha in Thyroid Diseases
por: Kobawala, Toral P., et al.
Publicado: (2011)

Bioavailability and feasibility of subcutaneous 5-fluorouracil.
por: Borner, M. M., et al.
Publicado: (1993)

A phase II randomised trial of 5-fluorouracil with or without interferon alpha-2a in advanced colorectal cancer.
por: Piga, A., et al.
Publicado: (1996)

Toxicity and feasibility of adjuvant high-dose interferon alpha-2b in patients with melanoma in clinical oncologic practice
por: Ravaud, A, et al.
Publicado: (1999)

Role of interleukin 2, interleukin 4, and alpha, beta, and gamma interferon in stimulating macrophage antibody-dependent tumoricidal activity
Publicado: (1988)

Double modulation of 5-fluorouracil with interferon alpha 2a and high-dose leucovorin: a phase I and II study.
por: Seymour, M. T., et al.
Publicado: (1994)

Immunochemotherapy with interleukin-2, interferon- α and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study
por: Herpen, C M L van, et al.
Publicado: (2000)

Radiofrequency ablation of stage IA non–small cell lung cancer in patients ineligible for surgery: results of a prospective multicenter phase II trial
por: Palussière, J., et al.
Publicado: (2018)

Systemic chemotherapy plus cetuximab after complete surgery in the treatment of isolated colorectal peritoneal carcinoma: COCHISE phase II clinical trial
por: Evrard, Serge, et al.
Publicado: (2019)

Treatment of advanced pancreatic cancer with 5-fluorouracil, folinic acid and interferon alpha-2A: results of a phase II trial.
por: Bernhard, H., et al.
Publicado: (1995)

Regulation of transforming growth factor is involved in the efficacy of combined 5-fluorouracil and interferon alpha-2b therapy of advanced hepatocellular carcinoma
por: Okada, Youhei, et al.
Publicado: (2018)

Effects of interleukin-2 and interferon-alpha A/D treatment on lymphocytes from tumour-bearing mice.
por: Ligo, M., et al.
Publicado: (1989)

Final report of a phase II study of interleukin 2 and interferon alpha in patients with metastatic melanoma.
por: Kruit, W. H., et al.
Publicado: (1995)

Using surveillance data to understand cancer trends: an overview in Morocco
por: Obtel, M., et al.
Publicado: (2015)

Identification of Interleukin1β as an Amplifier of Interferon alpha-induced Antiviral Responses
por: Robichon, Katharina, et al.
Publicado: (2020)

Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-α and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression
por: Ota, H, et al.
Publicado: (2005)

FOLFIRI(®) and Bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms
por: Bécouarn, Yves, et al.
Publicado: (2014)

Granulocyte-macrophage colony-stimulating factor alone or with dacarbazine in metastatic melanoma: a randomized phase II trial
por: Ravaud, A, et al.
Publicado: (2001)

Glycyrrhizin in patients who failed previous interferon alpha-based therapies: biochemical and histological effects after 52 weeks
por: Manns, M P, et al.
Publicado: (2012)

Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma.
por: Kruit, W. H., et al.
Publicado: (1996)

Survival in renal cell carcinoma-a randomized evaluation of tamoxifen vs interleukin 2, alpha-interferon (leucocyte) and tamoxifen.
por: Henriksson, R., et al.
Publicado: (1998)

Cannot write session to /tmp/vufind_sessions/sess_t66e67bde73tbcj5q4kqvj3p5d